Vertex pharmaceuticals incorporated investigated regarding potential securities law violations - contact levi & korsinsky for details - vrtx

New york, ny / accesswire / december 20, 2024 / levi & korsinsky notifies investors that it has commenced an investigation of vertex pharmaceuticals incorporated ("vertex pharmaceuticals") (nasdaq:vrtx) concerning possible violations of federal securities laws. on december 19, 2024, the company reported disappointing results from its rewind-lb phase 2b clinical trial for the pain drug suzetrigine.
VRTX Ratings Summary
VRTX Quant Ranking